Nebivolol, a third-generation beta-blocker with vasodilating properties, offers a favorable tolerability profile for hypertensive patients with ischemic heart disease or metabolic abnormalities.
Does nebivolol offer advantages in the management of hypertensive patients with or without comorbidities compared to other beta-blockers?
Nebivolol's unique pharmacological profile, including vasodilating properties and neutral metabolic effects, makes it a versatile and well-tolerated option for managing hypertension across various patient profiles.
Nebivolol According to the most recent international guidelines, β-blockers maintain a central role in the management of hypertension, being recommended at any treatment step when there is a specific indication, such as heart failure, angina, postacute myocardial infarction, atrial fibrillation or pregnancy. However, β-blockers are not a homogeneous class: individual molecules differ in terms of pharmacological and clinical profile and are therefore suitable for different patient subtypes. In particular nebivolol, third generation β1-selective β-blocker with vasodilating properties, neutral metabolic effects and good tolerability, proved to have advantages over other β-blockers, which makes the drug suitable in a wide variety of hypertensive patients with or without comorbidities. Lay abstract: β-blockers are the main class of antihypertensive agents currently available. Nebivolol is one of the most recent β-blocking agents and it has vasodilating effects which may be Useful in hypertensive patients with heart disease of ischemic (restriction in blood supply) origin or with erectile dysfunction. It has a good tolerability profile which makes it safe to use in patients with metabolic abnormalities (such as diabetes or dyslipidemia) or chronic obstructive pulmonary diseases.
Kasaniya* et al. (Mon,) conducted a review in Hypertension. Nebivolol was evaluated. Nebivolol, a third-generation beta-blocker with vasodilating properties, offers a favorable tolerability profile for hypertensive patients with ischemic heart disease or metabolic abnormalities.